Table 3. Summary of Treatment-Emergent Adverse Events (TEAEs) Over the 29-Day Treatment Duration.
| TEAEs | No. (%) | |
|---|---|---|
| Cyclosporine (n = 103) | Vehicle (n = 103) | |
| All causality | ||
| TEAEs, No. | 56 | 41 |
| Participants with at least 1 TEAE | 35 (34.0) | 31 (30.1) |
| Ocular TEAEs | 42 | 27 |
| Participants with at least 1 ocular TEAE | 26 (25.2) | 22 (21.4) |
| Treatment-related | ||
| TEAEs, No. | 21 | 11 |
| Participants with at least 1 TEAE | 15 (14.6) | 11 (10.7) |
| Ocular TEAEs | 21 | 11 |
| Participants with at least 1 ocular TEAE | 15 (14.6) | 11 (10.7) |
| Ocular TEAEs that occurred in >2% of study participants in either group | ||
| Visual acuity reduced | 13 (12.6) | 18 (17.5) |
| Ocular discomfort | 4 (3.9) | 2 (1.9) |
| Eye pain | 3 (2.9) | 2 (1.9) |
| Vision blurred | 3 (2.9) | 2 (1.9) |
| Instillation site reactions | 3 (2.9) | 0 |